Zhejiang Jingxin Pharmaceutical Co., Ltd.

SZSE:002020.SZ

12.55 (CNY) • At close October 26, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001
Revenue 3,952.093,779.8463,335.9713,258.0753,646.6842,943.8022,219.0661,875.4611,415.6961,235.496974.427857.582709.731631.019531.474510.306565.217428.869301.881348.222301.506269.954227.053
Cost of Revenue 2,048.3181,766.1491,472.7851,273.3281,273.4291,034.681911.947864.404698.745659.772574.438559.599522.428442.407367.278361.265439.042310.739204.591261.42220.844208.897185.919
Gross Profit 1,903.7722,013.6971,863.1861,984.7472,373.2551,909.1211,307.1191,011.057716.952575.724399.989297.983187.303188.612164.196149.041126.176118.1397.2986.80280.66261.05741.134
Gross Profit Ratio 0.4820.5330.5590.6090.6510.6490.5890.5390.5060.4660.410.3470.2640.2990.3090.2920.2230.2750.3220.2490.2680.2260.181
Reseach & Development Expenses 371.786367.061329.331259.242254.104242.019164.301110.31374.42553.83142.79737.77215.83314.911000000000
General & Administrative Expenses 65.91860.10360.23172.33869.34359.05758.54146.81944.29235.7334.21425.70921.13917.14560.23364.87748.25838.72926.34320.77217.81713.7159.078
Selling & Marketing Expenses 783.527791.576760.935965.0981,341.061,100.572679.676501.779364.364311.609204.68144.65963.52691.36379.26865.89260.149.53533.22829.125.57117.39116.104
SG&A 959.152851.679821.1661,037.4361,410.4031,159.629738.218548.598408.657347.339238.894170.36884.665108.508139.5130.77108.35888.26459.57149.87143.38831.10625.183
Other Expenses 6.352135.65699.759114.691172.118-0.852231.91919.419134.79612.7315.0036.9524.5094.47110.13912.0732.889-5.9072.6140.6952.6640.966
Operating Expenses 1,324.5861,354.3961,250.2561,411.3681,836.6251,537.2081,029.465769.757555.232456.755326.567250.13137.346157.511143.643134.217111.24290.95761.31850.72544.50432.35825.63
Operating Income 579.186756.616692.961765.386602.063416.293118.744236.266186.09124.39662.97636.33329.7469.9233.879-20.332-9.96115.79530.87532.34132.0125.60414.807
Operating Income Ratio 0.1470.20.2080.2350.1650.1410.0540.1260.1310.1010.0650.0420.0420.0160.007-0.04-0.0180.0370.1020.0930.1060.0950.065
Total Other Income Expenses Net 134.898-6.31.521-6.4071.35143.52873.00814.00634.9827.9462.284-7.969-13.259-16.669-12.202-25.075-12.821-10.374-11.571-1.179-3.627-0.962-0.461
Income Before Tax 714.083750.316694.482758.979603.414415.441350.662255.306196.701126.91575.70739.88436.69814.4328.351-10.2512.11217.74224.68434.92732.61928.00315.408
Income Before Tax Ratio 0.1810.1990.2080.2330.1650.1410.1580.1360.1390.1030.0780.0470.0520.0230.016-0.020.0040.0410.0820.10.1080.1040.068
Income Tax Expense 84.62382.49379.778105.65281.46643.95483.63638.57730.08419.83511.3598.2057.5791.4724.3798.0040.6587.276.239.1367.2145.725.435
Net Income 618.898662.254612.542653.07520.396370.037264.377211.946165.21107.0864.34831.67929.1212.8953.753-17.731.50410.49118.45525.79125.40522.2829.972
Net Income Ratio 0.1570.1750.1840.20.1430.1260.1190.1130.1170.0870.0660.0370.0410.020.007-0.0350.0030.0240.0610.0740.0840.0830.044
EPS 0.720.770.750.830.640.430.330.260.240.170.110.0520.0580.0270.008-0.0370.0030.0290.0570.0580.0770.0670.05
EPS Diluted 0.720.770.750.830.640.430.330.260.240.170.110.0520.0580.0270.008-0.0370.0030.0290.0570.0580.0770.0670.05
EBITDA 800.652939.471863.597881.102731.089520.934619.846357.522266.575186.969133.844100.44297.52472.73468.54369.20455.38252.59543.39248.38342.82231.74619.403
EBITDA Ratio 0.2030.2490.2590.270.20.1770.2790.1910.1880.1510.1370.1170.1370.1150.1290.1360.0980.1230.1440.1390.1420.1180.085